Oxaliplatin DNA/RNA synthesis inhibitor are many questions to be explored further with new therapies

Loss, progression-free survival Oxaliplatin DNA/RNA synthesis  inhibitor and PSA response rate.69 The randomization was performed in a 2:1 manner to 1000mg abiraterone plus prednisone versus placebo plus prednisone. There was an overall survival advantage in the abiraterone arm 3.9 months with an improvement in overall survival. Time to PSA progression in patients under treatment arm was 10.2 months with a progression-free survival time of 5.6 months and a PSA response of 29%. Currently, abiraterone in other early stages of prostate cancer, including normal use of abiraterone agent with neoadjuvant leuprolide, and 70 in combination with prednisone and a means of LHRH with radiation have been studied in localized or locally advanced prostate cancer.71 Discussion The last 18 months have entered Born radical Ver changes for metastatic prostate cancer in the world of medical oncology. Newly approved therapies discussed above, and new perspectives in biology are VER Changed the face of prostate cancer and will continue to reshape the treatment paradigms in the future. There are many questions to be explored further with new therapies and unknown reactions. Each new treatment option has a fight with his use of the benefits pro Benefits and pitfalls, issues of cooperation of its treatment, and the subtleties that its use and / or value in a given clinical scenario can limit. Despite the statistical significance of the cloudy with hrten sipuleucel T at the improvement in median overall survival and clinical benefit and cost are perhaps not so clear. Co t play The important decision is whether therapies are used in the community. The survival advantage of T sipuleucel about 4.1 months, with each infusion of T sipuleucel priced at $ 31,000 per infusion therapy. Obtained for a given patient, the recommended three doses, is the co t about $ 93,000. In comparison, co Ts cabazitaxel $ 34,500 for a course of treatment with six bottles, a survival advantage for 2.4 months. While this is significantly less than the cooperation of T sipuleucel T, the quality can t be worse with cabazitaxel of life, given its side effect profile. The measurement of Lebensqualit t is not dealt with in the IMPACT study, neither the TROPIC study. Quality was T life study in patients who completed the T sipuleucel with the short inventory of fatigue at baseline, week 13 and week 26th No significant changes changes In Lebensqualit t after starting treatment in patients who have observed again U sipuleucel T. abiraterone is also an option for patients who have no basis docetaxel. The advantage of the survival time 3.9 months compared with placebo is consistent with both T and sipuleucel cabazitaxel. The collaboration of T abiraterone k Can also significantly lower compared to other new drugs are discussed. Co t for 1 month at $ 5,000 abiraterone is protected shops. Abiraterone mechanism of action is v Llig different and unique Epothilone A compared to chemotherapy and therefore shows a different side effect profile. Abiraterone limited nausea / vomiting caused no serious h Dermatological toxicity is t usually less toxic and k Can afford the patient a better Lebensqualit t and break from the chemotherapy. Moreover, the convenience of abiraterone also be a consideration because it is the only available oral agent, which improves survival is the f.